ConductScience.org, home

Paper37001036

Baseline PET radiomics outperforms the IPI risk score for prediction of outcome in diffuse large B-cell lymphoma.

Eertink JJ and 20 others. Blood, 2023. Cited by 57 papers, by iCite.

Cite this record

ConductScience Library. Baseline PET radiomics outperforms the IPI risk score for prediction of outcome in diffuse large B-cell lymphoma. Papers, record 37001036. Release papers-2026-11-12-0.1.0, 12 Nov 2026. https://conductscience.org/library/papers/37001036

Download JSON
Sources
11 sources
Release
papers-2026-11-12-0.1.0

Paper

PubMed's record of the paper, with iCite's citation figures. No abstract is shown.

Title
Baseline PET radiomics outperforms the IPI risk score for prediction of outcome in diffuse large B-cell lymphoma.
PubMed
Journal
Blood
PubMed
Year
2023
PubMed
Publication types
Journal Article, Research Support, Non-U.S. Gov't
PubMed
Citations, by iCite
57
iCite
Relative citation ratio, by iCite
5.8
iCite
Revised in PubMed
2025-05-30
PubMed

Authors21

The authors in the order PubMed's record lists them, with the ORCID iDs it states.

Topics8

NLM's MeSH indexing of the paper, its major topics first.

MeSH termMajor
Neoplasm Recurrence, LocalMajor topic
Lymphoma, Large B-Cell, DiffuseMajor topic
Humans
Prognosis
Retrospective Studies
Positron-Emission Tomography
Risk Factors
Fluorodeoxyglucose F18

Source PubMed

Download CSV of topics

Grants1

Each grant PubMed's record writes, matched to the NIH project NIH's grant and paper links name for this paper, and each of those links the record does not write.

Grant, as the record writes itAgencyCountryNIH projectStated by
203148/Z/16/ZWellcome TrustUnited KingdomPubMed

Source PubMed

Download CSV of grants

Comments and corrections1

PubMed's comments and corrections, NLM's own indexing: retractions first, then expressions of concern, errata and updates, and comments last.

KindPMIDTitleIn Papers
Comment in37347501A man's best friend is his PET.https://conductscience.org/library/papers/37347501

Source PubMed

Download CSV of comments and corrections

References47

The papers the reference list in PubMed's record names, those in our copy of PubMed, in the list's order.

OrderPMIDTitleJournalYearIn PapersSource
128774879Outcomes in refractory diffuse large B-cell lymphoma: results from the international SCHOLAR-1 study.Blood2017https://conductscience.org/library/papers/28774879PubMed
231710995Dynamic risk assessment based on positron emission tomography scanning in diffuse large B-cell lymphoma: Post-hoc analysis from the PETAL trial.Eur J Cancer2020https://conductscience.org/library/papers/31710995PubMed
336306337Baseline radiomics features and MYC rearrangement status predict progression in aggressive B-cell lymphoma.Blood Adv2023https://conductscience.org/library/papers/36306337PubMed
433278600Risk stratification in diffuse large B-cell lymphoma using lesion dissemination and metabolic tumor burden calculated from baseline PET/CT†.Ann Oncol2021https://conductscience.org/library/papers/33278600PubMed
516754935Rituximab-CHOP versus CHOP alone or with maintenance rituximab in older patients with diffuse large B-cell lymphoma.J Clin Oncol2006https://conductscience.org/library/papers/16754935PubMed
625981519Prediction models need appropriate internal, internal-external, and external validation.J Clin Epidemiol2016https://conductscience.org/library/papers/25981519PubMed
732232482International prognostic indices in diffuse large B-cell lymphoma: a comparison of IPI, R-IPI, and NCCN-IPI.Blood2020https://conductscience.org/library/papers/32232482PubMed
834272315Quantitative Radiomics Features in Diffuse Large B-Cell Lymphoma: Does Segmentation Method Matter?J Nucl Med2022https://conductscience.org/library/papers/34272315PubMed
935357901Proposed New Dynamic Prognostic Index for Diffuse Large B-Cell Lymphoma: International Metabolic Prognostic Index.J Clin Oncol2022https://conductscience.org/library/papers/35357901PubMed
1032436212Prognostic indices in diffuse large B-cell lymphoma in the rituximab era: an analysis of the UK National Cancer Research Institute R-CHOP 14 versus 21 phase 3 trial.Br J Haematol2021https://conductscience.org/library/papers/32436212PubMed
1132680929Automated Segmentation of Baseline Metabolic Total Tumor Burden in Diffuse Large B-Cell Lymphoma: Which Method Is Most Successful? A Study on Behalf of the PETRA Consortium.J Nucl Med2021https://conductscience.org/library/papers/32680929PubMed
1234714558Generation and validation of a PET radiomics model that predicts survival in diffuse large B cell lymphoma treated with R-CHOP14: A SAKK 38/07 trial post-hoc analysis.Hematol Oncol2022https://conductscience.org/library/papers/34714558PubMed
1330785937RaCaT: An open source and easy to use radiomics calculator tool.PLoS One2019https://conductscience.org/library/papers/30785937PubMed
143203132Comparing the areas under two or more correlated receiver operating characteristic curves: a nonparametric approach.Biometrics1988https://conductscience.org/library/papers/3203132PubMed
1535406482Discovery of Pre-Treatment FDG PET/CT-Derived Radiomics-Based Models for Predicting Outcome in Diffuse Large B-Cell Lymphoma.Cancers (Basel)2022https://conductscience.org/library/papers/35406482PubMed
1635146578Optimal PET-based radiomic signature construction based on the cross-combination method for predicting the survival of patients with diffuse large B-cell lymphoma.Eur J Nucl Med Mol Imaging2022https://conductscience.org/library/papers/35146578PubMed
173120124818F-FDG PET Dissemination Features in Diffuse Large B-Cell Lymphoma Are Predictive of Outcome.J Nucl Med2020https://conductscience.org/library/papers/31201248PubMed
1826150440Final Results of a Prospective Evaluation of the Predictive Value of Interim Positron Emission Tomography in Patients With Diffuse Large B-Cell Lymphoma Treated With R-CHOP-14 (SAKK 38/07).J Clin Oncol2015https://conductscience.org/library/papers/26150440PubMed
1930941463
Prognostic value of metabolic tumour volume on baseline 18F-FDG PET/CT in addition to NCCN-IPI in patients with diffuse large B-cell lymphoma: further stratification of the group with a high-risk NCCN-IPI.
Eur J Nucl Med Mol Imaging2019https://conductscience.org/library/papers/30941463PubMed
2026936916Molecular Profile and FDG-PET/CT Total Metabolic Tumor Volume Improve Risk Classification at Diagnosis for Patients with Diffuse Large B-Cell Lymphoma.Clin Cancer Res2016https://conductscience.org/library/papers/26936916PubMed

See all 47 referencesDownload CSV of references

Cited by42

The papers in our copy of PubMed whose reference list names this one, newest first. iCite, which reads more sources, counts 57 citations.

PMIDTitleJournalYearIn PapersSource
42931850Organ-specific depth of response to CD19-directed CAR T-cell therapy in B-cell lymphomas.Cancer Immunol Immunother2026https://conductscience.org/library/papers/42931850PubMed
42910135Associations of Subcutaneous and Visceral Fat Areas with Progression-Free Survival in Patients with Diffuse Large B-Cell Lymphoma.Int J Med Sci2026https://conductscience.org/library/papers/42910135PubMed
42664000A machine learning-derived sarcopenia index is associated with survival and nonrelapse mortality in DLBCL.Blood Adv2026https://conductscience.org/library/papers/42664000PubMed
42636799Cell-free DNA genomic and fragmentomic features for early outcome prediction in large B cell lymphoma.Cell Rep Med2026https://conductscience.org/library/papers/42636799PubMed
4242089018F-FDG PET/CT radiomics combined with double-expressor status enhances prognostication and high-risk stratification in DLBCL.BMC Med Imaging2026https://conductscience.org/library/papers/42420890PubMed
42414740
Development and validation of a radiomics nomogram for predicting outcomes following combined radiotherapy and modern chemotherapy in early-stage extranodal nasal-type NK/T-cell lymphoma: a multicenter study.
Ann Hematol2026https://conductscience.org/library/papers/42414740PubMed
42360330PET-guided early identification of CAR-T candidates in diffuse large b-cell lymphoma: a multidisciplinary expert consensus.Eur J Nucl Med Mol Imaging2026https://conductscience.org/library/papers/42360330PubMed
42326344Baseline 18F-FDG PET/CT habitat radiomics versus dual-channel deep learning for predicting interim PET early metabolic response in diffuse large B-cell lymphoma: a comparative study.Front Oncol2026https://conductscience.org/library/papers/42326344PubMed
42322517Splenic FDG PET uptake and CT volume as prognostic biomarkers in diffuse large B cell lymphoma.Radiol Med2026https://conductscience.org/library/papers/42322517PubMed
41872336A convolutional neural network for fully automated total metabolic tumor volume delineation in patients with aggressive Non-Hodgkin lymphoma.Eur J Nucl Med Mol Imaging2026https://conductscience.org/library/papers/41872336PubMed
41786479Validation of an AI Method for Automated Lymphoma Metabolic Tumor Volume Segmentation Using a Public Benchmark PET/CT Dataset.J Nucl Med2026https://conductscience.org/library/papers/41786479PubMed
41689647A Lesion-adaptive Segmentation Approach for Tumor Delineation on FDG PET/CT in Diffuse Large B-cell Lymphoma Patients.Eur J Nucl Med Mol Imaging2026https://conductscience.org/library/papers/41689647PubMed
41260205A prognostic index integrating deep learning baseline PET/CT biomarkers and multi-omics profiling in diffuse large B cell lymphoma.Cell Rep Med2025https://conductscience.org/library/papers/41260205PubMed
40995463Large B-cell lymphoma (LBCL): EHA Clinical Practice Guidelines for diagnosis, treatment, and follow-up.Hemasphere2025https://conductscience.org/library/papers/40995463PubMed
40900042Automatic Lugano staging for risk stratification in lymphoma: a multicenter PET radiomics and machine learning study with survival analysis.Nucl Med Commun2025https://conductscience.org/library/papers/40900042PubMed
40629066Integration of [18F]FDG-PET radiomics with liquid biopsy improves outcome prediction in newly diagnosed diffuse large B-cell lymphoma.Leukemia2025https://conductscience.org/library/papers/40629066PubMed
40558299Prognostic Value of Multiple Manual Segmentation Methods for Diffuse Large B-Cell Lymphoma with 18F-FDG PET/CT.Curr Oncol2025https://conductscience.org/library/papers/40558299PubMed
40518458Divergent prognostic utility of metabolic risk scores in large B-cell lymphoma subtypes: a real-world analysis.Eur J Nucl Med Mol Imaging2025https://conductscience.org/library/papers/40518458PubMed
40506239Summary Report of the SNMMI AI Task Force Radiomics Challenge 2024.J Nucl Med2025https://conductscience.org/library/papers/40506239PubMed
40492497Baseline total lesion glycolysis identifies high-risk patients with immunosuppressive signatures in early-stage natural killer/T-cell lymphoma.Oncologist2025https://conductscience.org/library/papers/40492497PubMed

See all 42 cited byDownload CSV of cited by

Genes1

The genes the Gene search release ties to the paper: Swiss-Prot's references first, then PubTator's text mining.

GeneNCBI Gene IDLinked byIn Genes
MYC4609PubTator's text mininghttps://conductscience.org/library/genes/4609

Source NCBI Gene

Download CSV of genes

Data dates

The date of each source this release read.

PubMed
2026-11-06
PubMed
iCite
2026-11-05
iCite
PMC's ID file
2026-11-05
PMC's ID file
NIH RePORTER's grant and paper links
2026-11-01
NIH RePORTER's grant and paper links
Trials
2026-11-12
Gene search
2026-11-11
Pipelines
2026-09-18

None in this release

  • Trials
  • Drugs
  • Data

Sources 11

  • ChEMBL, through Open TargetsCC BY-SA 3.0
  • ClinicalTrials.govNo license stated
  • HGNCCC0
  • iCiteCC BY 4.0
  • NCBI GenePublic domain (US government)
  • NIH RePORTER's grant and paper linksPublic domain
  • Open TargetsCC0 1.0
  • PMC's ID filePublic domain (US government)
  • PubMedNLM's terms
  • PubTator 3Public domain
  • UniProtCC BY 4.0
Each source's terms
  • ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
  • ClinicalTrials.govnone stated
  • HGNCCC0: https://www.genenames.org/about/license/
  • iCiteCC BY 4.0
  • NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
  • NIH RePORTER's grant and paper linksPublic domain (NIH RePORTER)
  • Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
  • PMC's ID fileNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
  • PubMedNLM's terms
  • PubTator 3Public domain
  • UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.

For software

Read this paper from software.

The record and each of its lists are JSON, twenty rows a page. No key.

GET https://conductscience.org/api/papers/v1/37001036

GET https://conductscience.org/api/papers/v1/37001036/authors?page=2